Ovid Therapeutics Files 8-K on Shareholder Vote

TL;DR

Ovid Therapeutics held a shareholder vote on June 6th, details filed today.

AI Summary

Ovid Therapeutics Inc. filed an 8-K on June 7, 2024, reporting on a matter submitted to a vote of security holders on June 6, 2024. The filing details the company's principal executive offices located at 441 Ninth Avenue, 14th Floor, New York, NY 10001.

Why It Matters

This filing indicates a formal process of shareholder voting has occurred, which can impact corporate governance and future strategic decisions for Ovid Therapeutics.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not contain information about significant financial changes or operational risks.

Key Players & Entities

• Ovid Therapeutics Inc. (company) — Registrant
• June 06, 2024 (date) — Date of earliest event reported
• June 07, 2024 (date) — Date of Report
• 441 Ninth Avenue, 14th Floor, New York, New York 10001 (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share OVID The Nasdaq Stock Mar

Filing Documents

• ovid-20240607.htm (8-K) — 58KB
• 0000950170-24-070673.txt ( ) — 170KB
• ovid-20240607.xsd (EX-101.SCH) — 24KB
• ovid-20240607_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. Ovid Therapeutics Inc. (the " Company ") held its annual meeting of stockholders (the " Annual Meeting ") on June 6, 2024. As of April 9, 2024, the record date for the Annual Meeting, there were 70,810,661 shares of Company common stock outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 58,503,813 shares, or 82.62%, were present in person or represented by proxy, which constituted a quorum. Summarized below are descriptions of the proposals voted on at the Annual Meeting and the final results for each of the proposals. The proposals set forth below are described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 24, 2024 (the " Proxy Statement "). Proposal 1 : The Company's stockholders elected all of the nominees for director to serve a three-year term until the Company's 2027 annual meeting of stockholders, or until their respective successors are duly elected and qualified, by the votes set forth in the table below: Nominee For Withheld Broker Non-Votes Barbara Duncan 36,686,822 5,581,389 16,235,602 Robert Michael Poole 40,158,684 2,109,527 16,235,602 Proposal 2 : The Company's stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement, by the votes set forth in the table below: For Against Abstain Broker Non-Votes 40,499,565 1,760,461 8,185 16,235,602 Proposal 3 : The Company's stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024 by the votes set forth in the table below: For Against Abstain 57,201,432 1,293,006 9,375

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OVID THERAPEUTICS INC. Date: June 7, 2024 By: /s/ Thomas M. Perone Thomas M. Perone General Counsel & Corporate Secretary